Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methoxy polyethylene glycol epoetin beta - Roche

Drug Profile

Methoxy polyethylene glycol epoetin beta - Roche

Alternative Names: CERA-pegylated-epoetin-beta; Continuous-erythropoietin-receptor-activator-pegylated-epoetin-beta; Epoetin beta pegol; Mircera; R-744; RO-0503821; RO-50-3821

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; CSL Vifor; Roche
  • Class Antianaemics; Colony-stimulating factors; Erythropoietins; Haematopoietic cell growth factors; Polyethylene glycols
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia
  • Discontinued Chemotherapy-induced anaemia

Most Recent Events

  • 02 Aug 2022 Vifor Pharma has been acquired by CSL and renamed to CSL Vifor
  • 19 Jul 2021 Roche completes phase II trial for Anaemia (In adolescents, In children, In infants, Treatment-experienced) in Lithuania, Hungary, Poland, France, Italy, USA and Spain (SC) (EudraCT2016-004779-39) (NCT03552393)
  • 18 Feb 2021 Methoxy polyethylene glycol-epoetin beta is still in phase II trials for Anaemia (In adolescents, In children, In infants, Treatment-experienced) in Lithuania, Hungary, Poland, France, Italy, USA and Spain (SC) (EudraCT2016-004779-39) (NCT03552393)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top